Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests

卷:12

Review

关键词: CELL-FREE DNA;    PAN-CANCER;    LIQUID BIOPSIES;    METHYLATION MARKERS;    EXTRACELLULAR-VESICLE;    NONINVASIVE METHOD;    PANCREATIC-CANCER;    COMMON TYPES;    DIAGNOSIS;    PLASMA;   

DOI  :  10.3390/cells12060935

来源: SCIE

【 摘 要 】

Cancer remains a leading cause of death worldwide, partly owing to late detection which entails limited and often ineffective therapeutic options. Most cancers lack validated screening procedures, and the ones available disclose several drawbacks, leading to low patient compliance and unnecessary workups, adding up the costs to healthcare systems. Hence, there is a great need for innovative, accurate, and minimally invasive tools for early cancer detection. In recent years, multi-cancer early detection (MCED) tests emerged as a promising screening tool, combining molecular analysis of tumor-related markers present in body fluids with artificial intelligence to simultaneously detect a variety of cancers and further discriminate the underlying cancer type. Herein, we aim to provide a highlight of the variety of strategies currently under development concerning MCED, as well as the major factors which are preventing clinical implementation. Although MCED tests depict great potential for clinical application, large-scale clinical validation studies are still lacking.